Vascular endothelial growth factor expression in early stage ovarian carcinoma

Cancer

Volumn 80, Issue 1, 1997, Pages 98-106

  Paley, Pamela J ^a   Staskus, Katherine A ^a   Gebhard, Kristin ^a   Mohanraj, Dhanabal ^a   Twiggs, Leo B ^a   Carson, Linda F ^a   Ramakrishnan, Sundaram ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Ovarian carcinoma; Prognosis; Tumor angiogenesis; Vascular endothelial growth factor (VEGF); Vascular permeability factor

Indexed keywords

VASCULOTROPIN;

ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TUMOR BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; ANTISENSE ELEMENTS (GENETICS); CAPILLARY PERMEABILITY; CARCINOMA; DISEASE-FREE SURVIVAL; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; LOGISTIC MODELS; LYMPHOKINES; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PROGNOSIS; RNA PROBES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0030923795     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970701)80:1<98::AID-CNCR13>3.0.CO;2-A     Document Type: Article

References (33)

1. Wingo PA, Tong T, Bolden S. Cancer statistics 1995. Cancer J Clin 1995;45:8-30.
2. National Cancer Institute, Division of Cancer Prevention and Control: Annual Cancer Statistics Review. Bethesda (MD): National Cancer Institute, 1986 NIH Pub. No. 87-2789.
3. Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, et al. Adjuvant therapy in stage I and II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990;322:1021-7.
4. Young RC, Knapp RC, Fuks Z, DiSaia PJ. Cancer of the ovary. In: DeVita V, Hellman S, Rosenburg SA editors. Cancer: principles and practice of oncology. Philadelphia: J. B. Lippincott, 1985;1083-117.
5. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
6. Liotta LA, Steep PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of negative and positive regulation. Cell 1991;64:327-36.
7. Fidler IF, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994;79:185-8.
8. Senger D, Van De Water L, Brown L. Nagy J, Yeo K-T, Yeo T-K, et al. Vascular permeability factor (VPF, VEGF) in tumor biology, Cancer Metastasis Rev 1993;12:303-24.
9. Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989;84:1470-8.
10. Olson TA, Mohanraj D, Carson LF, Ramakrishnan S. Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res 1994;54:276-80.
11. Nagy JA, Masse EM, Hergberg KT, Myers MS, Yeo KT, Sioussat TM, et al. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 1995;55:360-8.
12. Weidner N, Folkman J, Pozza F, Bevilaqua P, Allred EN, Moore DH, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early breast carcinoma. J Natl Cancer Inst 1992;84:1875-7.
13. Weidner N, Carrol PR, Flax J, Blumfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401-9.
14. Olivarez D, Ulbright T, DeRiese W, Foster R, Reister T, Einborn L, et al. Neovascularization in clinical stage A testicular germ cell tumor: prediction of metastatic disease. Cancer Res 1994;54:2800-2.
15. Maeda K, Chung YS, Takatsuka S, Ogawa Y, Sawada T, Yamashita Y, et al. Tumor angiogenesis as a predictor of recurrence in gastric carcinoma. J Clin Oncol 1991;13:477-81.
16. Macchiarini P, Fontaini G, Hardin MJ, Sqartini F, Angeletti CA. Relation of neovasculature to metastasis of non-small cell lung cancer. Lancet 1992;340:145-6.
17. Staging Announcement: FIGO Cancer Committee. Gynecol Oncol 1986;25:383-5.
18. Haase A, Brahic M, Stowring L, Blum H. Detection of viral nucleic acids by in situ hybridization. In: Methods of virology. New York: Academic Press, 1984:189-226.
19. 35S. J Histochem Cytochem 1990;38:917-22.
20. Dembo AJ, Davy S, Stenwig AE, Berle EJ, Bush RS, Kjorstad K. Prognostic factors in patient with stage I epithelial ovarian cancer. Obstet Gynecol 1990;75:263-73.
21. Hreshchyshyn MM, Park RC, Blessing JA, Norris HJ, Levy D, Lagasse LD, et al. The role of adjuvant therapy in stage I ovarian cancer. Am J Obstet Gynecol 1980;138:139-45.
22. Berchuck A, Kamel A, Whitacker R, Kerns B, Olt G, Kinney R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-90.
23. Schueler JA, Trimbos JB, Burg M, Cornelisse CJ, Herman J, Fleuren GJ. DNA index reflects the biologic behavior of ovarian carcinoma stage I-IIa. Gynecol Oncol 1996;62:59-66.
24. Kohler MF, Kerns BJ, Humphrey PA, Marks JR, Bast RC, Berchuck A. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol 1993;81:643-50.
25. Abu-Jawdeh GM, Faix JD, Niloff J, Tognazzi K, Manseau E, Dvorak HF, et al. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest 1996;74:1105-15.
26. Friedlander ML, Dembo AK. Prognostic factors in ovarian cancer. Semin Oncol 1991;18:205-10.
27. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis ad metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
28. Boocock CA, Chamock-Jones S, Sharkey AM, McLaren J, Barker PJ, Wright KA., et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 1995;87:506-16.
29. Kamat BR, Brown LF, Manseau EF, Senger DR, Dvorak HF. Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Am J Pathol 1995;146:157-65.
30. Booth M, Berel V, Smith P. Risk factors for ovarian cancer: a case-control study. Br J Cancer 1989;60:592-8.
31. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-5.
32. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4.
33. Olson TA, Mohanraj D, Ramikrishnan S. In vivo neutralization of vascular endothelial growth factor (VEGF)/ vascular permeability factor (VPF) inhibits ovarian carcinoma-associated ascites formation and tumor growth. Int J Oncol 1996;8:505-11.